ArticleJournal of current ophthalmology
Ocular Manifestations of Coronavirus Disease 2019: A Hospital-Based Prospective Study at a Coronavirus Disease Dedicated Tertiary Center.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate ophthalmic manifestations in coronavirus disease 2019 (COVID-19) patients admitted to a designated COVID-19 center in Northern India during the period from April 13, 2020, to April 13, 2022. This aims to provide a comprehensive understanding of ocular involvement in the context of the pandemic. Methods: This is a hospital-based prospective observational study. All COVID-19-positive (reverse transcriptase polymerase chain reaction positive - via pharyngeal and nasal swabs) patients, who were admitted to our hospital, were included in the study. Upon receiving ophthalmology referrals, patients were seen in the COVID-19 ward, with data collected on demographic distribution, presenting ocular symptoms, and specific ocular findings. Results: Out of 3278 patients admitted to our center, 287 developed ocular symptoms. The study revealed a mean age of 63.8 ± 13.9 years, with males constituting 61.3% of the cases. The mean logMAR best-corrected visual acuity was found to be 0.30 ± 0.60. The mean duration between COVID-19 diagnosis and development of the first ophthalmic symptom was 10.4 ± 9.8 days. The predominant ocular symptoms included redness, discharge, and watering. Anterior segment manifestations were predominant, with conjunctivitis being the most prevalent ocular pathology (74.21%), followed by episcleritis (9.41%) and subconjunctival hemorrhage (7.31%). Conjunctivitis presented bilaterally in 41.5% of these patients, emphasizing its significance in the spectrum of COVID-19 ocular manifestations. Conclusions: This research contributes substantial evidence regarding ophthalmic manifestations in COVID-19 patients. Ophthalmologists should remain vigilant, considering the potential for ocular symptoms to precede respiratory manifestations. The study emphasizes the need for comprehensive patient assessments and preventive measures in ophthalmic practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.